Results from a recent phase 2b clinical trial study showed that the pan-PPAR agonist lanifibranor could modulate key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH, indicating the beneficial effect of the activation of PPARs on NAFLD [17]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.